Physician profile
Brett Chamernik
NPI 1487018925
$41,910.32
in general payments reported to CMS, 2019-2025
25 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $12K · 2023: $1,141 · 2024: $307 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Travel and Lodging: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.58 |
| Travel and Lodging | $423.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $20,219.95 | 2021-2025 | |
| Smith+Nephew, INC. | $4,708.60 | 2021-2025 | Journey II, Aetos Shoulder System, Accu-Pass |
| Medical Device Business Services, INC. | $4,625.08 | 2021 | |
| Medwest Associates | $4,015.31 | 2022-2023 | |
| Micromed INC | $3,728.06 | 2021-2022 | |
| Stryker Corporation | $1,676.27 | 2021-2025 | Gamma, Mako, Rio |
| Saxum Surgical, INC. | $1,205.68 | 2022 | |
| Oak Med, INC. | $465.64 | 2025 | |
| Depuy Synthes Sales INC. | $308.59 | 2022-2025 | Monovisc, Orthovisc, Ideal |
| Catalyst Orthoscience | $252.35 | 2021-2024 | Catalyst Csr Shoulder System |
| Fidia Pharma USA INC. | $176.03 | 2022-2025 | Hymovis, Triluron, Hyalgan |
| Avanos Medical | $112.12 | 2022-2024 | Genvisc 850 Sodium Hyaluronate |
| Orthofix Medical, INC. | $65.90 | 2024-2025 | Physio-Stim, Accelstim |
| Pacira Pharmaceuticals Incorporated | $65.59 | 2023-2024 | Exparel, Iovera, Zilretta |
| Zimmer Biomet Holdings, INC. | $45.31 | 2023 | Tricera Handpiece |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.17 | 2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $32.23 | 2022-2023 | |
| Heron Therapeutics, INC. | $29.03 | 2023 | Zynrelef |
| Organogenesis INC. | $24.70 | 2023 | Puraply |
| Vertex Pharmaceuticals Incorporated | $24.17 | 2024 | |
| Kerecis Limited | $21.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bioventus LLC | $20.35 | 2023 | Gelsyn-3 |
| Ferring Pharmaceuticals INC. | $20.05 | 2025 | Euflexxa |
| Checkpoint Surgical, INC | $13.40 | 2024 | Checkpoint Stimulators |
| Endo Pharmaceuticals INC. | $13.12 | 2023 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Chamernik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.